53
Active Trials
18
Phase 1
19
Phase 2
20
Phase 3
9
Therapeutic Areas
Portfolio Concentration: 62% of active trials in Oncology
Oncology
33 active / 202 total
Solid Tumor (Advanced)
12 active
42 total since 2015
Non-Hodgkin Lymphoma
4 active
3 Ph3
16 total since 2015
Myelofibrosis
3 active
6 total since 2015
Hematologic Malignancies
3 active
6 total since 2015
Colorectal Cancer
2 active
1 Ph3
7 total since 2015
Ovarian Cancer
2 active
1 Ph3
6 total since 2015
Lung Cancer (General)
1 active
11 total since 2015
NSCLC
1 active
1 Ph3
8 total since 2015
Squamous Cell Carcinoma
1 active
5 total since 2015
Endometrial Cancer
1 active
5 total since 2015
Pancreatic Cancer
1 active
3 total since 2015
Breast Cancer
1 active
3 total since 2015
MDS
1 active
2 total since 2015
Bladder Cancer
0 active
15 total since 2015
Head and Neck Cancer
0 active
8 total since 2015
Renal Cell Carcinoma
0 active
8 total since 2015
Melanoma
0 active
7 total since 2015
Hepatocellular Carcinoma
0 active
6 total since 2015
Cholangiocarcinoma
0 active
5 total since 2015
Esophageal Cancer
0 active
5 total since 2015
Mesothelioma
0 active
5 total since 2015
Merkel Cell Carcinoma
0 active
4 total since 2015
Multiple Myeloma
0 active
3 total since 2015
Cervical Cancer
0 active
3 total since 2015
Gastric Cancer
0 active
3 total since 2015
Hodgkin Lymphoma
0 active
2 total since 2015
Triple Negative Breast Cancer
0 active
2 total since 2015
CLL
0 active
1 total since 2015
Glioblastoma
0 active
1 total since 2015
Brain Tumor
0 active
1 total since 2015
Sarcoma
0 active
1 total since 2015
Prostate Cancer
0 active
1 total since 2015
SCLC
0 active
1 total since 2015
Immunology
10 active / 43 total
Cardiovascular
9 active / 21 total
Dermatology
4 active / 14 total
Rare Disease
1 active / 4 total
Respiratory
1 active / 1 total
Urology
0 active / 8 total
CNS
0 active / 3 total
Infectious Disease
0 active / 2 total
Click an indication to see competitive landscape (all sponsors in that indication).
Data: ClinicalTrials.gov (2015+)